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Abstract
Background: While there has been much research regarding risk factors and prognostic factors
for breast cancer in general, research specific to Iran is sparse. Further, the association between
breast cancer survival and socio-demographic and pathologic factors has been widely studied but
the majority of these studies are from developed countries. Southern Iran has a population of
approximately 4 million. To date, no research has been performed to determine breast cancer
survival and to explore the association between the survival and socio-demographic and pathologic
factors in Southern Iran, where this study was conducted.
Methods: The data were obtained from the cancer registry in Fars province, Southern Iran and
included 1148 women diagnosed with breast cancer between 2000 and 2005. The association
between survival, and sociodemographic and pathological factors, distant metastasis at diagnosis,
and treatment options was investigated using Cox regression.
Results: The majority of patients were diagnosed with an advanced tumour size. Five-year overall
survival was 58% (95%CI; 53%–62%). Cox regression showed that family income (good vs poor:
hazard ratio 0.46, 95%CI; 0.23–0.90) smoking (HR = 1.40, 95%CI; 1.07–1.86), metastases to bone
(HR = 2.25, 95%CI; 1.43–3.52) and lung (HR = 3.21, 95%CI;1.70–6.05), tumour size ( 2 cm vs  5
cm: HR = 2.07, 95%CI;1.39–3.09) and grade (poorly vs well differentiated HR = 2.33, 95%CI; 1.52–
3.37), lymph node ratio (0 vs 1: HR = 15.31, 95%CI; 8.89–26.33) and number of involved node (1
vs >15: HR = 14.98, 95%CI; 8.83–25.33) were significantly related to survival.
Conclusion: This is the first study to evaluate breast cancer survival in Southern Iran and has used
a wide range of explanatory factors, 44. The results demonstrate that survival is relatively poor and
is associated with diagnosis with late stage disease. We hypothesise that this is due to low level of
awareness, lack of screening programs and subsequent late access to treatment.
Published: 5 June 2009
BMC Cancer 2009, 9:168 doi:10.1186/1471-2407-9-168
Received: 16 June 2008
Accepted: 5 June 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/168
© 2009 Rezaianzadeh et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 11
(page number not for citation purposes)
BMC Cancer 2009, 9:168 http://www.biomedcentral.com/1471-2407/9/168Background
Breast cancer is the most commonly diagnosed malig-
nancy among women in developed countries [1-3], and in
some developing countries [4-6]. According to the report
of the Iranian Centre for the Prevention and Control of
Disease, Ministry of Health and Medical Education, 2000,
Iran; breast cancer is the most prevalent cancer among Ira-
nian women and accounts for 21.4% of all malignancies.
The prevalence of breast cancer in Europe and the USA is
estimated between 8 to 10%. However, the lowest preva-
lence is seen in Asian countries, at about 1% [7]. In Iran
the prevalence of breast cancer was reported as 6.7/1000
in 2002, which is even less than this [8]. While there has
been substantial research published on risk factors and
prognostic factors for breast cancer in general, research
specific to Iran is sparse. Further, the association between
breast cancer survival and socio-demographic and patho-
logic factors has been widely studied but the majority of
these studies are from developed countries.
Iran has a total population of just over 70 million and
almost all studies of breast cancer in Iran are from the cap-
ital, Tehran with a population of approximately 14 mil-
lion. Most of these studies have not focused on survival
and prognostic factors. To our knowledge, only two stud-
ies from Tehran have investigated breast cancer survival
[9,10]. Southern Iran has a population of approximately
4 million and to date no study has determined breast can-
cer survival in this region or explored the relationships
between the survival and socio-demographic and patho-
logical factors. This paper presents the results of a study
which fills this gap by determining five-year breast cancer
survival for women with breast cancer in Southern Iran,
and the impact of 44 explanatory factors.
Ethical approval for this study was obtained from the
Research Ethics Committee of Shiraz University of Medi-
cal Sciences, Iran, and the Research Ethics Committee of
the School of Health Sciences and Social Care of Brunel
University, UK.
Methods
This study used patients' records from Shiraz University
Cancer Registry Centre, which is a hospital-based registry
in a tertiary care centre which delivers oncology services to
a population of approximately four million. This is the
only centre which delivers oncology services in Southern
Iran. Therefore, most probably all cancer patients come to
this hospital for treatment. However a few of them may
travel to other centers for treatment. The Cancer Registry
was started on 1 January 2000 and so this study includes
women who were diagnosed with breast cancer between 1
January 2000 and 31 Dec. 2005. During that period, of the
6253 patients diagnosed with ten most common cancers
in the area, 1192 were registered as having female breast
cancer. Thirty women were excluded due to previous
breast cancer (23), ductal carcinoma in situ (2), and other
previous cancers (5). In addition, 14 women with bilat-
eral tumours were excluded due to the small numbers.
Thus, the study population comprised 1148 women who
were diagnosed with a first primary invasive breast malig-
nancy and who underwent breast surgery including axil-
lary dissection.
All patients were followed-up at regular three month
intervals for the first year following diagnosis and had reg-
ular six month follow-ups thereafter. The last date of fol-
low-up was 29th July 2006. All subjects in this study
underwent surgery and received radiation and all except a
very small proportion received chemotherapy. These three
treatment options have been offered in three sequences:
surgery followed by chemotherapy and then by radiation,
chemotherapy followed by surgery and then by radiation,
and surgery followed only by radiation, in common with
current practice in this region. About 82% received surgery
followed by chemotherapy and then by radiation, 16%
chemotherapy followed by surgery and then by radiation,
and 2% received surgery followed only by radiation. At
the time of diagnosis all patients were evaluated for
metastasis to five distant sites: bone, liver, lung, brain, and
ovary.
The main objective of this study was to investigate the
impact of a wide range of factors on breast cancer survival.
Therefore, the only outcome considered here is survival.
All variables recorded at the cancer registry (44) were used
in this study. The 44 explanatory variables divide natu-
rally into three groups: socioeconomic or demographic,
clinical/pathological factors, and distant metastases.
The association between each of the explanatory variables
and outcome was assessed in turn using Cox's regression
(unifactorial analysis).
Variables that were significantly associated with survival
were considered firstly in each of the three conceptual
groups: socioeconomic and demographic factors together,
clinical/pathological factors, and distant metastases. Each
model included all variables from the particular group
that were statistically significant unifactorially, and then
the variable that had the greatest regression estimate p-
value was removed from the model. This process contin-
ued by remodeling and repeating removal of the next var-
iable with the greatest p-value until all variables left in the
model had p-value less than 0.05. A final model was fitted
by combining all variables which were statistically signif-
icant in the three groups separately.Page 2 of 11
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stages in two ways: i) visually by inspecting graphs of the
cumulative baseline functions against log survival time
and ii) by a test based on the Schoenfeld residuals.
The results are presented as hazard ratios and 95% confi-
dence intervals. All analysis was conducted using Stata v9.
Results
Impact of socio-demographic factors on survival
Of the 1148 patients included in the analysis 859 were
alive at the end of follow-up, 269 had died, and 20 were
lost to follow-up. Median follow-up time, from first path-
ological diagnosis until the time of death or the end of
study, was 34 months. Mean age at diagnosis was 47 years
(ranged from 19 to 86 years).
In unifactorial analysis of all socioeconomic and demo-
graphic factors, only family income and smoking were sig-
nificantly associated with survival. (Table 1) These two
factors together were entered into the first model and both
remained significant. Compared to the patients with a low
family income those with a higher family income were at
54% lower risk of death. (Table 2) Smokers were also at a
40% higher risk of death compared to non-smokers.
Impact of distant metastases on survival
Metastases to liver, lung and bone were all significantly
associated with poorer survival in the unifactorial analy-
ses (Table 3). Metastases to bone and lung remained sig-
nificant in the multifactorial model. Compared to the
patients without distant metastasis those with lung metas-
tasis had just over three times, and those with bone metas-
tasis had just over twice the risk of death (Table 2).
Impact of clinical/pathological factors on survival
Of 15 clinical/pathological factors, greater tumour size
and higher grade, tumour calcification and necrosis, skin
and nipple involvement, vascular and lymphatic inva-
sion, higher number of excised and involved nodes,
greater lymph node ratio (LNR), treatment, and type of
surgery were significantly associated with poorer survival
in the unifactorial analyses (Table 4). The factors that
remained significant were tumour size, histological grade,
number of involved nodes, and lymph node ratio.
Patients with tumour size 5 cm and above had a two-fold
increase in risk of death compared to the patients with
tumour size 2 cm and less. Patients with poorly differenti-
ated tumour grades had a doubling of risk of death com-
pared to those with well differentiated tumour grades.
There was a steady rise in risk with increased number of
involved nodes ranging from a three-fold to a fifteen-fold
increase in risk compared to node negative patients (Table
2). Hazard ratios increased steadily as the lymph node
ratio increased with the hazard being greatest for patients
with a ratio of one compared with zero.
We modeled all statistically significant variables of the
three previous models together to explore how the effect
of socio-demographic variables might influence survival.
This analysis showed that while the effect estimates for all
variables were virtually unchanged, the socio-demo-
graphic variables and bone and lung metastases became
non-significant. (Table 2) We interpret this as showing
that the effects of the real and measurable effects of socio-
demographic factors on survival were expressed in tumour
characteristics.
Using the life-table method, five-year overall survival of
this study population was 58% (95%CI; 53%–62%). The
three-year overall survival was 76% (95%CI; 73%–79%).
There was no evidence that the proportional hazards
assumption was violated in any of the analyses reported
above.
Discussion
This study has shown that of all socioeconomic factors
only family income was associated with survival after
adjustment for other factors. This is in agreement with
other studies which obtained family income data by inter-
viewing patients [11-13] as in this study. However, other
studies which have obtained income data from a census
have shown no association [2,14,15].
Of all demographic factors assessed, only smoking was
related to breast cancer prognosis in this study, showing
an adverse effect on survival which remained significant
after adjustment for income. Two other studies in the UK
and Sweden found a similar result [16,17]. It is perhaps
surprising that income remains significant after adjusting
for smoking. This may be a true effect or may be due to
inadequate control for smoking using the binary data
available – smoker/non-smoker. Exploratory analysis pro-
vided evidence that the effects of smoking and income on
survival were mediated through adverse tumour charac-
teristics.
The impact of young age at diagnosis on breast cancer sur-
vival has been long debated. This study found no evidence
of a relationship between younger age at diagnosis and
survival. Moreover age at diagnosis was not related to
tumour characteristics. These findings accord with some
studies [13,18,19] but not others [20,21] although in the
latter studies the age categorization and settings were dif-
ferent.
BMI was not significantly related to survival in agreement
with Carmichael's study in 2004 [22]. However four otherPage 3 of 11
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Unifactorial analysis Distribution of factors
Hazard ratio (95%CI) p Numbers %
Area of residence 1148* 100
Affluent 1 0.179 213 19
Middle 1.12 (0.79–1.58) 590 51
Deprived 1.36 (0.95–1.94) 345 30
Family income 1143 99
Low & poor 1 0.031 426 37
Moderate 0.88 (0.69–1.13) 669 58
High 0.44 (0.22–0.87) 48 4
Occupation 1148 100
Housewife 1 0.853 898 78
Non-manual 0.92 (0.67–1.28) 199 17
Manual 1.07 (0.63–1.80) 51 4
Education 661 57
Illiterate 1 0.939 203 18
Primary 1.01 (0.65–1.58) 223 19
High school 1.15 (0.71–1.85) 148 13
University 1.00 (0.58–1.74) 87 7
Smoking 1145 100
Non-smoker 1 0.009 904 79
Smoker 1.44 (1.09–1.89) 241 21
Marital status 1147 100
Single 1 0.056 104 9
Married 0.64 (0.44–0.93) 936 82
Divorced & Widowed 0.77 (0.46–1.28) 107 9
Blood group 408 36
O 1 0.739 153 13
A 1.18 (0.71–1.95) 105 9
B 1.32 (0.80–2.19) 100 9
AB 1.08 (0.53–2.20) 45 4
BMI (Body Mass Index) 951 83
<25 1 0.784 509 44
25–30 1.10 (0.82–1.47) 317 28
>30 1.09 (0.72–1.66) 125 11
No. of children 1143 100
 3 1 0.218 571 50
4–8 0.95 (0.74–1.22) 518 45
>8 1.87 (1.18–2.96) 54 5
Age at diagnosis 1118 97
 35 years 1 0.499 172 15
36–49 years 0.96 (0.67–1.37) 519 45
50–64 years 1.02 (0.69–1.50) 342 30
 65 years 1.35 (0.82–2.22) 85 7Page 4 of 11
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BMI > 30 compared to those with BMI < 25 [23-25]. The
differences in findings for BMI in our study could be due
to their late stage diagnosis for our study population.
This study found no evidence for a relationship between
family history of breast cancer and survival and also
observed that patients with positive and negative family
history had similar tumour characteristics. This is consist-
ent with the results of several other studies [21,26,27].
Our findings revealed that tumour size, histological grade,
and lymph node status were associated with breast cancer
survival after mutual adjustment. This result is consistent
with some other studies [28,29]. We found that poorly
differentiated tumours carried a higher risk of death com-
pared to well-differentiated tumours. Patients with
tumour size 5 cm and above had a higher risk of death
than those with tumour size 2 cm and less.
In this study lymph node status was investigated in three
different ways: number of involved nodes, lymph node
ratio, and number of excised nodes. The number of
involved nodes and lymph node ratio were the most pow-
erful predictors of survival on multifactorial analysis.
According to our findings not only did node positive
patients have a poorer survival rate compared to node
negatives, but also as the number of involved nodes
increased the risk of death increased too. A similar trend
has been reported elsewhere [30,31]. Lymph node ratio
(LNR) was negatively correlated with survival in agree-
ment with studies from Canada [32], Belgium [33,34] and
the USA [35]. The number of excised lymph nodes was
non-significant after adjustment for other pathological
factors.
This study found no association between histological type
and survival in common with other works [29,36]. We
found no evidence for an effect of intra-mammary tumour
location. However, three studies reported an adverse effect
Age at first pregnancy 122 11
 18 years 1 0.081 55 5
19–25 years 0.30 (0.08–1.06) 47 4
>25 years 0.21 (0.03–1.66) 20 2
OCP use 255 22
 3 years 1 0.869 80 7
>3 years 0.96 (0.59–1.57) 175 15
Ethnicity 1140 99
Fars 1 0.821 1006 88
Non-Fars 1.04 (0.73–1.48) 134 12
Religion 1147 100
Islam (Shia) 1 0.931 1031 90
Islam (Sunni) 0.93 (0.65–1.32) 110 9.5
Others 1.23 (0-.) 6 0.05
Menarche age 938 82
 13 years 1 0.934 561 49
>13 years 0.99 (0.75–1.30) 377 33
History of BC in SDR 1148 100
No 1 0.758 996 87
Yes 0.94 (0.65–1.36) 152 13
History of BC in FDR 1148 100
No 1 0.22 881 77
Yes 0.83 (0.62–1.11) 267 23
Duration of breast feeding 205 18
 3 years 1 0.175 78 7
4–6 years 2.03 (0.96–4.29) 68 6
>6 years 1.62 (0.71–3.69) 59 5
Abbreviations: OCP = Oral Contraceptive pill, BC = Breast Cancer, FDR = First Degree Relatives, SDR = Second Degree Relatives
* Total number available of 1148 subjects
Table 1: Uni-factorial analyses and distribution of socio-demographic factors (Continued)Page 5 of 11
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central location was a negative predictor of survival
[39,40] compared to other locations. These differences
might be due to missing data in our study since data
regarding tumour location was only available for about
one-third of the women. Skin and nipple involvement,
tumour calcification and necrosis, vascular and lymphatic
invasion were negatively associated with survival, but
these effects became non-significant after adjustment. We
note that these factors were closely correlated with each
other and also with tumour size and grade, and lymph
node status which may explain our findings.
Patients who underwent surgery as the first treatment
option had a better prognosis than those who were treated
firstly by chemotherapy. It might be due to a larger
tumour size; because, women with larger tumours or met-
astatic diseases at diagnosis were mostly treated with
chemotherapy followed by surgery. Moreover, all patients
with tumour size above 1 cm received chemotherapy,
which is a standard practice at the institution of study.
Table 2: Multi-factorial analysis by three conceptual groups and final model
Variables from the other three multifactorial analyses Result of final model
Hazard ratio (95%CI) P ** Hazard ratio (95%CI) p
Family income
Low & poor 1 0.039 99%
Moderate 0.90 (0.70–1.15)
Good 0.46 (0.23–0.90)
Smoking
Non-smoker 1 0.016 99%
Smoker 1.40 (1.07–1.86)
Metastasis to bone
No 1 0.000 100%
Yes 2.25 (1.43–3.52)
Metastasis to lung
No 1 0.000 100%
Yes 3.21 (1.70–6.05)
Tumour size
 2 cm 1 0.000 88% 1 0.000
>2 & <5 cm 1.43 (0.97–2.09) 1.43 (0.97–2.09)
 5 cm 2.07 (1.39–3.09) 2.07 (1.39–3.10)
Tumour grade
Well-differentiated 1 0.000 88% 1 0.000
Moderately-differentiated 1.30 (0.88–1.93) 1.30 (0.88–1.93)
Poorly-differentiated 2.33 (1.52–3.37) 2.33 (1.52–3.57)
No. of involved lymph nodes
0 1 0.000 88% 1 0.000
1–5 2.96 (1.78–4.94) 2.96 (1.78–4.94)
6–10 5.29 (3.11–9.01) 5.29 (3.11–9.01)
11–15 8.29 (4.98–13.80) 8.29 (4.98–13.80)
>15 14.96 (8.83–25.33) 14.96 (8.83–25.33)
Lymph node ratio
0 1 0.000 88% 1 0.000
> 0 & .3 2.02(1.30–3.13) 2.03 (1.09–3.76)
> .3 & .6 4.84 (2.72–8.60) 4.84 (2.72–8.60)
> .6 &< 1 9.30 (5.48–15.80) 9.30 (5.48–15.80)
1 15.31 (8.89–26.33) 15.31 (8.90–26.34)
** Proportion of subjects in multifactorial analysisPage 6 of 11
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ference in treatment may contribute to the relatively poor
prognosis seen.
Most other studies have reported significant effects on sur-
vival of tumour size, histological grade, and lymph node
status but for other pathological factors. Our findings dif-
fered a little which could be due to the adjustment we per-
formed – other studies have tended to adjust for only a
few pathological factors whereas in our study we included
13 pathological factors that were significantly associated
with survival in unifactorial analysis.
Three- and five-year overall survival rates in southern Iran
were found to be 76% and 58%, respectively. To our
knowledge only two studies have previously reported 5-
year overall breast cancer survival rates in Iran and these
were 60% [9] and 62% [10]. These studies were conducted
in Tehran. The 5-year overall survival rates in Iran com-
pare with 46% in India [41], 64% in Oman [4], 65% in
Greece [42], 71% in Germany [43], 78% in Belgium [41],
89% in the USA [44], and 84% in the UK [45] and show
that Iran has considerably poorer survival than European
countries and the United States.
There are several possible reasons for this. In Iran
women's awareness of breast cancer is limited – Iranian
women have little or no information regarding breast self
examination and its effect on early detection and progno-
sis. A study of health staff in Tehran found that only 6 per-
cent of them reported doing breast self examination on a
regular basis [46] and a study in Middle Eastern Asian
Islamic immigrant women in the USA reported that none
did regular breast self-examination [47]. Although, Hack-
shaw, 2003, concluded that breast self-examination can-
not improve survival after breast cancer, women who do
it, are more aware of changes in their breast and seek care
earlier if there is any problem [48].
There are strong cultural barriers which hinder Iranian
women from consulting with a physician for sensitive
female-specific health problems. Even highly educated
women are reluctant to seek treatment for breast tumours.
Further to this, access to cancer treatment units is slow,
delaying diagnosis and there is no screening mammogra-
phy. It seems probable that all of these factors increase the
chances of delayed diagnosis and hence late stage disease
which is the main difference between Iranian women and
women in Western countries.
There are some limitations to this study. Data for some
explanatory factors were missing and some were recorded
in a wrong way that made them less useful. For example,
for age at first pregnancy data were available for 122
patients and for OCP usage it was available for 255
patients. In relation to OCP usage it was recorded as usage
of OCP for three years and less and for above three years.
It was not clear whether the others had never used OCP or
they had used it but they were not asked for any informa-
tion. A proportion of subjects had received hormonal
therapy, but no data regarding hormone receptor status
and hormonal therapy were recorded in the registry and
so this factor could not be investigated. Also the type of
chemotherapy drugs, doses, and duration of chemother-
apy was not recorded at the registry and was not analyzed
in this study.
Table 3: Uni-factorial analysis and distribution of distant metastases
Unifactorial analysis Distribution of factors
Hazard ratio (95%CI) P numbers %
Metastasis to bone 1148 100
No 1 0.001 1110 97
Yes 2.18 (1.39–3.41) 38 3
Metastasis to liver 1148 100
No 1 0.001 1134 99
Yes 2.80 (1.48–5.27) 14 1
Metastasis to lung 1148 100
No 1 0.001 1134 99
Yes 3.06 (1.62–5.76) 14 1
Metastasis to brain 1148 100
No 1 0.283 1142 99.5
Yes 2.14 (0.53–8.63) 6 0.5Page 7 of 11
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Unifactorial analysis Distribution of factors
Hazard ratio (95%CI) p numbers %
Tumour side 1064 93
Right 1 0.562 565 49
Left 1.08 (0.84–1.39) 499 4
Tumour location 440 38
Lateral 1 0.258 322 28
Medial 0.75 (0.42–1.36) 68 6
Central 0.60 (0.30–1.97) 50 4
Tumour size 1055 92
 2 cm 1 0.000 298 26
>2 & <5 cm 1.82 (1.30–2.70) 523 46
 5 cm 3.04 (2.05–4.50) 234 20
Tumour grade 1059 92
Well-differentiated 1 0.000 250 22
Moderately-differentiated 1.89 (1.28–2.78) 637 55
Poorly-differentiated 4.53 (2.99–6.86) 172 15
Nuclear grade 140 12
Low 1 0.068 33 3
Intermediate 10.88 (1.00–80.75) 91 8
High 5.70 (0.59–54.90) 16 1
Co-morbidity 352 31
GI&Respiratory 1 0.433 37 3
Cardiovascular 0.92 (0.44–1.95) 122 11
Psycho.&Neurological 0.69 (0.28–1.57) 55 5
Gynaecologic 1.42 (0.61–3.29) 39 3
Endocrine&Metabolic 1.13 (0.55–2.33) 99 9
No. of stillbirths 1097 96
0 1 0.581 997 87
1–3 1.19 (0.78–1.83) 92 8
>3 1.48 (0.47–4.62) 8 1
No. of abortions 1106 96
0 1 0.525 819 71
1–3 0.85 (0.64–1.14) 269 23
>3 0.80 (0.30–2.15) 18 2
Histological type 1062 93
IDC 1 0.086 942 82
ILC 0.68 (0.31–1.55) 33 3
Med.C 0.35 (0.14–0.84) 60 5
MLDC 1.55 (0-.) 3 <1
Muc.C 0.65 (0.09–4.62) 6 <1
IPC 1.33 (0.42–4.15) 10 1
Met.C 3.31 (1.05–10.39) 8 1Page 8 of 11
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0 1 0.007 20 2
1–10 1.48 (0.46–4.74) 263 23
11–20 1.93 (0.61–6.09) 553 48
21–30 2.29 (0.713–7.37) 189 16
>30 4.67 (1.28–17.03) 23 2
Lymph node ratio 1027 89
0 1 0.000 331 29
>0 &  .3 1.98 (1.06–3.66) 246 21
>.3 &  .6 5.24 (2.96–9.29) 156 14
>.6 & < 1 11.26 (6.68–18.96) 185 16
1 18.87 (11.09–32.08) 109 9
No. of involved lymph nodes 1046 91
0 1 0.000 349 30
1–5 3.03 (1.82–5.04) 346 30
6–10 6.59 (3.89–11.15) 146 13
11–15 10.16 (6.13–16.84) 123 11
>15 18.78 (11.21–31.45) 82 7
Tumour calcification 1022 89
No 1 0.000 740 64
Yes 1.67 (1.28–2.19) 282 25
Tumour necrosis 317 28
No 1 0.017 157 14
Yes 1.82 (1.11–2.97) 160 14
Nipple involvement 995 87
No 1 0.000 887 77
Yes 1.84 (1.32–2.57) 108 10
Skin involvement 1013 88
No 1 0.000 946 82
Yes 2.06 (1.39–3.05) 67 6
Vascular invasion 1035 90
No 1 0.000 604 53
Yes 1.90 (1.47–2.46) 431 37
Lymphatic invasion 1006 88
No 1 0.000 419 36
Yes 3.73 (2.67–5.20) 587 52
Treatment 1134 99
S&C&R 1 0.000 927 81
C&S&R 1.86 (1.39–2.50) 178 16
S&R 1.27 (0.56–2.87) 29 2
Type of surgery 1065 93
MRM 1 0.000 649 57
RM 1.09 (0.64–1.86) 62 5
TM 1.60 (1.13–2.28) 99 9
L 0.58 (0.37–0.90) 164 14
Q 0.32 (0.14–0.73) 85 7
PM 2.66 (0.85–8.36) 6 1
Abbreviations: IDC = Invasive Ductal Carcinoma, ILC = Invasive Lobular Carcinoma, Med.C = Medullary Carcinoma, MLDC = Mixed Lobular 
Ductal Carcinoma, Muc.C = Mucinous Carcinoma, IPC = Invasive Papillary Carcinoma, Met.C = Metaplastic Carcinoma, S&C&R = Surgery and 
Chemotherapy and Radiotherapy, C&S&R = Chemotherapy and Surgery and Radiotherapy, S&R = Surgery and Radiotherapy, MRM = Modified 
Radical Mastectomy, RM = radical Mastectomy, TM = Total Mastectomy, L = Lumpectomy, Q = Quadrantectomy, PM = Partial Mastectomy
Table 4: Uni-factorial analysis and distribution of clinico-pathological factors (Continued)Page 9 of 11
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recorded for each patient per GP visit and so there were no
data on any other preexisting diseases. In addition, preex-
isting diseases were categorized into five categories: gas-
trointestinal and respiratory, cardiovascular,
psychological and neurological, gynaecological, endo-
crine and metabolic. This categorization differs from the
international classification of diseases, and other diseases
such as musculoskeletal and skin diseases were not con-
sidered. Again it was not clear whether the patients did
not have these diseases or they had but it was not
recorded. All of these limitations have since been
addressed for future data collection but cannot be reme-
died for the current study.
It is strength and a weakness that this is the first study
based on cancer registry data in Shiraz University of Med-
ical Sciences, where full data collection was begun in
2000. The strengths lie in the richness of the data with
many potential predictor variables tested and the unique-
ness of the findings for this population. The weakness is
that only 5 years of data were available for analysis, giving
a relatively small sample size of 1148 women. This there-
fore limits the statistical power of the study. With 1148
women and power 90%, significance level 5%, a hazard
ratio of 1.4 can be detected. Therefore we acknowledge
that this study has insufficient statistical power to detect
effects which are smaller than this and so it is possible that
smaller effects have been missed. In future years when
more data have been gathered, power will be greater and
smaller effects can be estimated with greater confidence.
In addition, in future years, the follow-up period will be
longer allowing survival to be estimated with greater pre-
cision and to allow the estimation of survival beyond the
5 years possible at this time.
Conclusion
In conclusion, the results presented in this study demon-
strate a relatively low five-year overall survival rate for
women diagnosed with breast cancer in Iran. Following
the analysis of 44 explanatory factors, the results pre-
sented in this study suggests that survival from breast can-
cer in southern Iran is affected by delayed diagnosis and
therefore late stage disease. We hypothesize that this is
due to low level of awareness, cultural barriers and slow
access to treatment. Further research is needed in Iranian
women to test these hypotheses and thus design appropri-
ate interventions to ultimately improve survival.
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